---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-004073"
form_type: "8-K"
ticker: "MXCT"
cik: "0001287098"
company_name: "MAXCYTE, INC."
filed_at: "2022-03-22T23:59:59+00:00"
generated_at: "2026-06-26T20:39:12.277222+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# MaxCyte Q4 revenue record $10.2M (+19%), FY2021 $33.9M (+30%); guides 2022 core growth 22-25%

## Summary
- Record Q4 revenue $10.2M (+19% YoY); FY revenue $33.9M (+30% YoY).
- Core cell therapy revenue grew 43% in Q4, drug discovery 32%; SPL program revenue $2.5M FY.
- Net loss $4.9M Q4, $19.1M FY; EBITDA loss $4.5M Q4, $17.4M FY; stock-based comp $2.4M Q4, $8.0M FY.
- 2022 guidance: core revenue growth 22-25% YoY, SPL program revenue ~$4M.
- SPL partners now 16 covering >95 programs; potential pre-commercial milestones >$1.25B.

## SEC filing metadata
- accession: 0001558370-22-004073
- form_type: 8-K
- ticker: MXCT
- cik: 0001287098
- company_name: MAXCYTE, INC.
- filed_at: 2022-03-22T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1287098/000155837022004073/0001558370-22-004073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1287098/000155837022004073/mxct-20220322x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-004073
- JSON: https://secwatch.observer/filing/0001558370-22-004073.json
- Plain text: https://secwatch.observer/filing/0001558370-22-004073.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.